Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,717 shares of the medical research company’s stock after acquiring an additional 26 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $893,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Golden State Equity Partners raised its position in Thermo Fisher Scientific by 63.1% in the fourth quarter. Golden State Equity Partners now owns 949 shares of the medical research company’s stock valued at $494,000 after purchasing an additional 367 shares during the period. Avantra Family Wealth Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $329,000. Spire Wealth Management increased its stake in Thermo Fisher Scientific by 4.4% in the fourth quarter. Spire Wealth Management now owns 1,550 shares of the medical research company’s stock valued at $806,000 after purchasing an additional 65 shares during the last quarter. Eagle Bluffs Wealth Management LLC lifted its position in Thermo Fisher Scientific by 7.6% in the fourth quarter. Eagle Bluffs Wealth Management LLC now owns 3,998 shares of the medical research company’s stock valued at $2,081,000 after acquiring an additional 284 shares during the last quarter. Finally, Osborne Partners Capital Management LLC increased its position in Thermo Fisher Scientific by 2.4% during the fourth quarter. Osborne Partners Capital Management LLC now owns 29,250 shares of the medical research company’s stock worth $15,217,000 after buying an additional 697 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TMO shares. Wells Fargo & Company increased their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Scotiabank lifted their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday. Finally, Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Trading Down 2.2 %

Shares of NYSE:TMO opened at $580.63 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The firm has a market cap of $222.09 billion, a P/E ratio of 35.13, a P/E/G ratio of 4.06 and a beta of 0.77. The company has a 50 day moving average of $542.95 and a 200-day moving average of $571.55. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is 9.44%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.